Efficacy and Safety of Oral Sotalol in Early Infancy
Identifieur interne : 001F80 ( Istex/Checkpoint ); précédent : 001F79; suivant : 001F81Efficacy and Safety of Oral Sotalol in Early Infancy
Auteurs : Marion Tipple [Canada] ; George Sandor [Canada]Source :
- Pacing and Clinical Electrophysiology [ 0147-8389 ] ; 1991-11.
English descriptors
- KwdEn :
Abstract
Sotalol, a nonselective β blocking agent with additional Class III activity has been shown to be extremely elective in the treatment of supraventricular tachycardias in adults and children. Little information is available on its use in infants. From August, 1985 to April, 1990, 18 infants, 2 months of age or less, were treated with oral sotalol for supraventricular arrhythmias. Their age ranged from a few hours to 2 months, mean 5 weeks, at the start of treatment. Weights were between 2.58–5 kg, mean 3.9 kg and dosage 2–4 mg/kg/24 hrs given in two equal doses, 12 hourly. Sixteen infants had structurally normal hearts, one had multiple cardiac rhabdo‐myomas, and one was postoperative Mustard procedure for transpostion of the great arteries. Thirteen of 18 infants had reentrant forms of supraventricular tachycardia, six of these had overt preexcitation. Two infants had chaotic atrial tachycardia, two atrial flutter, and one with ectopic atrial tachycardia. Previous antiarrhythmic therapy had been unsuccessful in 12 patients. All infants, except one with chaotic atrial tachycardia, were successfully controlled with sotalol. Ten infants discontinued therapy between the ages of 7 and 18 months as it was felt to be no longer necessary. Mean duration of treatment was 12.8 months. Three had recurrences of their arrhythmia and were again successfully controlled by sotalol. Mild sinus bradycardia occurred in all infants. No other side effects were noted. Sotalol is an effective, safe drug for the treatment of supraventricular tachycardias in early infancy.
Url:
DOI: 10.1111/j.1540-8159.1991.tb02816.x
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:9C36B6B19D8DB983817C24C733CD2DA4697A6CC6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Oral Sotalol in Early Infancy</title><author><name sortKey="Tipple, Marion" sort="Tipple, Marion" uniqKey="Tipple M" first="Marion" last="Tipple">Marion Tipple</name></author><author><name sortKey="Sandor, George" sort="Sandor, George" uniqKey="Sandor G" first="George" last="Sandor">George Sandor</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C36B6B19D8DB983817C24C733CD2DA4697A6CC6</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1111/j.1540-8159.1991.tb02816.x</idno><idno type="url">https://api-v5.istex.fr/document/9C36B6B19D8DB983817C24C733CD2DA4697A6CC6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000501</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000501</idno><idno type="wicri:Area/Istex/Curation">000501</idno><idno type="wicri:Area/Istex/Checkpoint">001F80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and Safety of Oral Sotalol in Early Infancy</title><author><name sortKey="Tipple, Marion" sort="Tipple, Marion" uniqKey="Tipple M" first="Marion" last="Tipple">Marion Tipple</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Paediatric Cardiology, British Columbia Children's Hospital, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Sandor, George" sort="Sandor, George" uniqKey="Sandor G" first="George" last="Sandor">George Sandor</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Paediatric Cardiology, British Columbia Children's Hospital, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Pacing and Clinical Electrophysiology</title><idno type="ISSN">0147-8389</idno><idno type="eISSN">1540-8159</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1991-11">1991-11</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="2062">2062</biblScope><biblScope unit="page" to="2065">2065</biblScope></imprint><idno type="ISSN">0147-8389</idno></series><idno type="istex">9C36B6B19D8DB983817C24C733CD2DA4697A6CC6</idno><idno type="DOI">10.1111/j.1540-8159.1991.tb02816.x</idno><idno type="ArticleID">PACE2062</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0147-8389</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>infants</term><term>sotalol</term><term>supraventricular tachycardia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sotalol, a nonselective β blocking agent with additional Class III activity has been shown to be extremely elective in the treatment of supraventricular tachycardias in adults and children. Little information is available on its use in infants. From August, 1985 to April, 1990, 18 infants, 2 months of age or less, were treated with oral sotalol for supraventricular arrhythmias. Their age ranged from a few hours to 2 months, mean 5 weeks, at the start of treatment. Weights were between 2.58–5 kg, mean 3.9 kg and dosage 2–4 mg/kg/24 hrs given in two equal doses, 12 hourly. Sixteen infants had structurally normal hearts, one had multiple cardiac rhabdo‐myomas, and one was postoperative Mustard procedure for transpostion of the great arteries. Thirteen of 18 infants had reentrant forms of supraventricular tachycardia, six of these had overt preexcitation. Two infants had chaotic atrial tachycardia, two atrial flutter, and one with ectopic atrial tachycardia. Previous antiarrhythmic therapy had been unsuccessful in 12 patients. All infants, except one with chaotic atrial tachycardia, were successfully controlled with sotalol. Ten infants discontinued therapy between the ages of 7 and 18 months as it was felt to be no longer necessary. Mean duration of treatment was 12.8 months. Three had recurrences of their arrhythmia and were again successfully controlled by sotalol. Mild sinus bradycardia occurred in all infants. No other side effects were noted. Sotalol is an effective, safe drug for the treatment of supraventricular tachycardias in early infancy.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Tipple, Marion" sort="Tipple, Marion" uniqKey="Tipple M" first="Marion" last="Tipple">Marion Tipple</name></noRegion><name sortKey="Sandor, George" sort="Sandor, George" uniqKey="Sandor G" first="George" last="Sandor">George Sandor</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001F80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:9C36B6B19D8DB983817C24C733CD2DA4697A6CC6
|texte= Efficacy and Safety of Oral Sotalol in Early Infancy
}}
| This area was generated with Dilib version V0.6.29. |  |